RaySearch is transferred to the Mid Cap segment at Nasdaq Stockholm
Effective January 4, 2016, RaySearch Laboratories AB ser. B (RAY B) will change from the Small Cap segment to the Mid Cap segment on Nasdaq Stockholm following Nasdaq’s annual review of its Nordic market capitalization, as reported by Nasdaq on December 17, 2015.
About the market cap segments
Companies belong to a market cap segment (Small-, Mid- and Large Cap) based on its average market value during the given review month. Each segment is reviewed annually based on the average market cap in November with adjustments taking effect in January the following year. The market cap calculations are based on the total number of shares, i.e. both listed and non-listed shares, of a company. Companies with a market value exceeding EUR 1 billion are in the group of “Large Cap”, while companies with a market value smaller than EUR 150 million belong to “Small Cap”. Companies with a market value between EUR 150 billion and EUR 1 billion belong to the “Mid Cap” segment.
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software solutions are used by over 2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is currently listed in the Small Cap segment on Nasdaq Stockholm, but will change to the Mid Cap Segment effective January 4, 2016.
For more information about RaySearch, visit www.raysearchlabs.com.
For further information please contact:
RaySearch Laboratories AB (publ)
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
Email: johan.lof@raysearchlabs.com